About Capricor Therapeutics
Capricor Therapeutics is a company based in Los Angeles (United States) founded in 2005 was acquired by Nile Therapeutics in July 2013.. The company has 160 employees as of December 31, 2024. Capricor Therapeutics offers products and services including Deramiocel and Exosomes Technology. Capricor Therapeutics operates in a competitive market with competitors including Tenaya Therapeutics, Cellino, Arrakis Therapeutics, MyoKardia and Eiger BioPharmaceuticals, among others.
- Headquarter Los Angeles, United States
- Employees 160 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Capricor Therapeutics, Inc.
-
Annual Revenue
$22.27 M-11.55as on Dec 31, 2024
-
Net Profit
$-40.47 M-81.57as on Dec 31, 2024
-
EBITDA
$-41.14 M-78.8as on Dec 31, 2024
-
Latest Funding Round
$5.1 M (USD), Post-IPO
Dec 19, 2019
-
Investors
HHS
& 2 more
-
Employee Count
160
as on Dec 31, 2024
-
Acquired by
Nile Therapeutics
(Jul 08, 2013)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Capricor Therapeutics
Capricor Therapeutics is a publicly listed company on the NASDAQ with ticker symbol CAPR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Capricor Therapeutics
Capricor Therapeutics offers a comprehensive portfolio of products and services, including Deramiocel and Exosomes Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapy targeting Duchenne Muscular Dystrophy through cell-based treatments.
Platform for developing exosome-based treatments for various diseases.
Unlock access to complete
Unlock access to complete
Funding Insights of Capricor Therapeutics
- Total Funding Total Funding
- Total Rounds 17
- Last Round Post-IPO — $5.1M
-
First Round
First Round
(15 Jul 2009)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2019 | Amount | Post-IPO - Capricor Therapeutics | Valuation |
investors |
|
| May, 2017 | Amount | Post-IPO - Capricor Therapeutics | Valuation |
investors |
|
| Sep, 2016 | Amount | Grant - Capricor Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Capricor Therapeutics
Capricor Therapeutics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Nile Therapeutics and Broadview Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed-stage life sciences investments are made in the US.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Developer of therapeutics for the treatment of cardiovascular diseases
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Capricor Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Capricor Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Capricor Therapeutics Comparisons
Competitors of Capricor Therapeutics
Capricor Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Cellino, Arrakis Therapeutics, MyoKardia and Eiger BioPharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| domain | founded_year | HQ Location |
Developer of autologous cell therapies
|
|
| domain | founded_year | HQ Location |
Provider of tools for the analysis of RNA structures
|
|
| domain | founded_year | HQ Location |
Specialized drugs are developed for genetic heart diseases.
|
|
| domain | founded_year | HQ Location |
Developer of antiviral agents against targets in the treatment of hepatitis
|
|
| domain | founded_year | HQ Location |
Cell therapy for diabetes is developed from stem cells.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Capricor Therapeutics
Frequently Asked Questions about Capricor Therapeutics
When was Capricor Therapeutics founded?
Capricor Therapeutics was founded in 2005 and raised its 1st funding round 4 years after it was founded.
Where is Capricor Therapeutics located?
Capricor Therapeutics is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
How many employees does Capricor Therapeutics have?
As of Dec 31, 2024, the latest employee count at Capricor Therapeutics is 160.
What is the annual revenue of Capricor Therapeutics?
Annual revenue of Capricor Therapeutics is $22.27M as on Dec 31, 2024.
What does Capricor Therapeutics do?
Founded in 2005 and based in Los Angeles, United States, Capricor Therapeutics operates in the biotechnology sector focused on regenerative medicine. Allogenic cardiosphere-derived cell products, including exosomes, form the basis of its platform technology. A lead candidate is currently in phase II clinical trials for post-myocardial infarction treatment. Additional candidates are being investigated for heart failure and Duchenne muscular dystrophy.
Who are the top competitors of Capricor Therapeutics?
Capricor Therapeutics's top competitors include Esperion Therapeutics, Tenaya Therapeutics and Cellino.
What products or services does Capricor Therapeutics offer?
Capricor Therapeutics offers Deramiocel and Exosomes Technology.
Is Capricor Therapeutics publicly traded?
Yes, Capricor Therapeutics is publicly traded on NASDAQ under the ticker symbol CAPR.
Who are Capricor Therapeutics's investors?
Capricor Therapeutics has 3 investors. Key investors include HHS, Nile Therapeutics, and Broadview Ventures.
What is Capricor Therapeutics's ticker symbol?
The ticker symbol of Capricor Therapeutics is CAPR on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.